Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer.

Schuette W, Krzakowski MJ, Massuti B, Otterson GA, Lizambri R, Wei H, Berger DP, Chen Y.

J Thorac Oncol. 2012 Jan;7(1):157-64. doi: 10.1097/JTO.0b013e31822f6526.

2.

A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.

Hasegawa T, Futamura Y, Horiba A, Yoshida T, Suzuki T, Kato T, Kaito D, Ohno Y, Iida T, Hayashi S, Sawa T.

J Radiat Res. 2016 Jan;57(1):50-4. doi: 10.1093/jrr/rrv062. Epub 2015 Oct 5.

3.

Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.

Takayama K, Inoue K, Tokunaga S, Matsumoto T, Oshima T, Kawasaki M, Imanaga T, Kuba M, Takeshita M, Harada T, Shioyama Y, Nakanishi Y.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1353-9. doi: 10.1007/s00280-013-2335-2. Epub 2013 Oct 29.

PMID:
24166107
4.

Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.

Brizel DM, Murphy BA, Rosenthal DI, Pandya KJ, Glück S, Brizel HE, Meredith RF, Berger D, Chen MG, Mendenhall W.

J Clin Oncol. 2008 May 20;26(15):2489-96. doi: 10.1200/JCO.2007.13.7349.

PMID:
18487568
5.

Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.

Le QT, Kim HE, Schneider CJ, Muraközy G, Skladowski K, Reinisch S, Chen Y, Hickey M, Mo M, Chen MG, Berger D, Lizambri R, Henke M.

J Clin Oncol. 2011 Jul 10;29(20):2808-14. doi: 10.1200/JCO.2010.32.4095. Epub 2011 Jun 13.

PMID:
21670453
6.

[Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].

Wang J, Pang QS, Wang P, Wang J, Wang W.

Zhonghua Zhong Liu Za Zhi. 2007 Oct;29(10):769-72. Chinese.

PMID:
18396691
7.
8.

Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.

Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-89-S12-95.

PMID:
9331129
9.

Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.

Gynecol Oncol. 2005 Jan;96(1):168-72.

PMID:
15589596
10.

Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.

Kong FM, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, Ramnath N, Hassan KA, Matuszak M, Ritter T, Bi N, Wang W, Orringer M, Cease KB, Lawrence TS, Kalemkerian GP.

JAMA Oncol. 2017 Oct 1;3(10):1358-1365. doi: 10.1001/jamaoncol.2017.0982.

11.

Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.

Kim YH, Ahn SJ, Kim YC, Kim KS, Oh IJ, Ban HJ, Chung WK, Nam TK, Yoon MS, Jeong JU, Song JY.

Jpn J Clin Oncol. 2016 Feb;46(2):144-51. doi: 10.1093/jjco/hyv174. Epub 2015 Nov 19.

PMID:
26590014
12.

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.

Fournel P, Vergnenégre A, Robinet G, Léna H, Gervais R, Le Caer H, Souquet PJ, Chavaillon JM, Bozonnat MC, Daurès JP, Chouaid C, Martel-Lafay I; GFPC and IFCT Team.

Eur J Cancer. 2016 Jan;52:181-7. doi: 10.1016/j.ejca.2015.10.072. Epub 2015 Dec 12.

PMID:
26689864
13.

A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer.

Carter DL, Garfield D, Hathorn J, Mundis R, Boehm KA, Ilegbodu D, Asmar L, Reynolds C.

Clin Lung Cancer. 2012 May;13(3):205-13. doi: 10.1016/j.cllc.2011.10.005. Epub 2011 Dec 3.

PMID:
22138037
14.

Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.

Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ.

J Natl Cancer Inst. 2010 Jun 16;102(12):859-65. doi: 10.1093/jnci/djq179. Epub 2010 May 26.

15.

Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer.

Casas F, Viñolas N, Ferrer F, Agustí C, Sanchez M, Maria Gimferrer J, Lomeña F, Campayo M, Jeremic B.

J Thorac Oncol. 2011 Jan;6(1):79-85. doi: 10.1097/JTO.0b013e318200e563.

16.

Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.

Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr.

J Clin Oncol. 2005 Sep 1;23(25):5883-91. Epub 2005 Aug 8. Erratum in: J Clin Oncol. 2006 Apr 20;24(12):1966.

PMID:
16087941
17.

Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.

Zhang J, Gay HA, Russo S, Parent T, Aljumaily R, Walker PR.

Lung Cancer. 2014 Jan;83(1):67-72. doi: 10.1016/j.lungcan.2013.09.007. Epub 2013 Sep 25.

PMID:
24246506
18.

Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.

Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE; Cancer, Leukemia Group B, Chicago, IL.

J Thorac Oncol. 2010 Sep;5(9):1382-90. doi: 10.1097/JTO.0b013e3181eba657.

19.

Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.

Bastos BR, Hatoum GF, Walker GR, Tolba K, Takita C, Gomez J, Santos ES, Lopes G, Raez LE.

J Thorac Oncol. 2010 Apr;5(4):533-9. doi: 10.1097/JTO.0b013e3181ce3e00.

20.

[Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].

Mito A, Yamasaki M, Matsuura K, Kajihara T, Nitta T, Awaya H, Arita K, Kashiwado K, Ohashi N.

Gan To Kagaku Ryoho. 2009 Oct;36(10):1653-6. Japanese.

PMID:
19838022

Supplemental Content

Support Center